ARKG ETF Holdings

Holdings

Symbol	Grade	Price % Change	Allocation
TWST	D	1.37	8.37
RXRX	F	-0.87	7.42
CRSP	D	3.43	7.34
ADPT	C	7.32	5.03
CDNA	D	2.44	4.77
VCYT	B	1.67	4.51
SDGR	C	2.31	4.14
BEAM	D	6.23	4.01
NTLA	F	3.62	3.89
IONS	F	0.21	3.85
NTRA	B	-1.24	3.82
NRIX	D	-1.43	3.78
TXG	F	7.67	3.56
GH	B	5.39	3.49
ARCT	F	-0.94	3.19
PSNL	D	2.66	2.70
ABSI	F	0.39	2.19
PACB	F	1.69	2.16
BFLY	B	-1.52	1.71
VEEV	C	0.95	1.70
AMGN	D	1.60	1.68
ACCD	D	-0.27	1.47
VRTX	F	0.13	1.29
ILMN	D	2.30	1.25
CERS	C	7.19	1.18
INCY	C	1.89	1.11
REGN	F	-0.87	0.92
PRME	F	7.74	0.90
CMPS	F	-0.90	0.75
MASS	F	-6.57	0.69
QSI	C	33.88	0.68
EXAS	D	-0.30	0.65
RPTX	F	-5.39	0.64
MRNA	F	7.48	0.01

Represented by ETF Holdings

Keywords: Biotechnology Cancer Biology Biopharmaceutical Drug Discovery Life Sciences Medicine Genomics Nasdaq 100 Molecular Biology S&P 500 Telehealth Telemedicine Acid Genetics Lab Testing Precision Medicine Blood Test Breakthrough Therapy CRISPR

Industries: Biotechnology Diagnostics & Research Health Information Services Health Information Services Medical Devices Drug Manufacturers - Major Medical Care Facilities

Recent News for ARK Genomic Revolution Multi-Sector ETF & its Holdings

Date	Stock	Title
Nov 23	INCY	What Moved Markets This Week
Nov 23	VRTX	3 Monster Stocks in the Making
Nov 22	MRNA	Jefferies says market nears short term “peak RFK negativity", Vaccine makers up
Nov 22	GH	Guardant Health (GH) Set To Dominate The Growing Liquid Biopsy Market
Nov 22	MRNA	Goldman Sachs: Moderna, Inc. (NASDAQ:MRNA) Is A Top Growth Investor Stock
Nov 22	MRNA	Moderna Stock Jumps Following Bullish Sales View at Healthcare Conference
Nov 22	MRNA	Moderna up 8% as Jefferies says market is close to 'peak RFK negativity'
Nov 22	MRNA	Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store
Nov 22	RXRX	2 Innovative Stocks That Could Deliver Outsize Returns
Nov 22	BFLY	Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
Nov 22	AMGN	Why Amgen (AMGN) is a Top Value Stock for the Long-Term
Nov 22	NTLA	Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
Nov 22	AMGN	RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?
Nov 22	VRTX	Goldman Sachs: Vertex Pharmaceuticals Incorporated (VRTX) Is A Top Growth Investor Stock
Nov 22	INCY	Goldman Sachs: Incyte Corporation (INCY) Is A Top Growth Investor Stock
Nov 22	VRTX	Got $500? 1 Biotech Stock to Buy and Hold Forever
Nov 21	MRNA	Why Is Moderna, Inc. (MRNA) Among the Worst Performing Biotech Stocks in 2024?
Nov 21	NTRA	Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
Nov 21	IONS	Why Is Ionis Pharmaceuticals, Inc. (IONS) Among the Worst Performing Biotech Stocks in 2024?
Nov 21	CRSP	Why Is CRISPR Therapeutics AG (CRSP) Among the Worst Performing Biotech Stocks in 2024?

Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business. The companies held in ARKG may develop, produce or enable: CRISPR Targeted Therapeutics Bioinformatics Molecular Diagnostics Stem Cells Agricultural Biology ARKG will be concentrated in issuers in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry. ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics revolution.
Exchange Traded Fund ETF Biotechnology Stem Cell Genomics Bioinformatics

ETF Components for ARKG - ARK Genomic Revolution Multi-Sector ETF